Please sign in to follow a disease.
Large-cell immunoblastic lymphoma
MONDO:0022037Malignant lymphoma characterized by the presence of immunoblasts with uniformly round-to-oval nuclei, one or more prominent nucleoli, and abundant cytoplasm. This class may be subdivided into plasmacytoid and clear-cell types based on cytoplasmic characteristics. A third category, pleomorphous, may be analogous to some of the peripheral T-cell lymphomas (LYMPHOMA, T-CELL, PERIPHERAL) recorded in both the United States and Japan.
Also known as: Diffuse Immunoblastic Lymphosarcoma, Diffuse Immunoblastic Lymphosarcomas, Diffuse non-Hodgkin lymphoma, immunoblastic, Diffuse non-Hodgkin's immunoblastic (diffuse) lymphoma, Diffuse non-Hodgkin's lymphoma, immunoblastic, Diffuse non-Hodgkin's lymphoma, immunoblastic (clinical), IMMUNOBLASTIC LARGE LYMPHOMA, Immunoblastic Large Cell Lymphoma
1922 clinical trials for this condition and its sub-types, 9 tagged with Large-cell immunoblastic lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
HIV-Fighting cells show promise in lymphoma treatment
Disease control CompletedThis study tested a new approach for people with both HIV and lymphoma. After high-dose chemotherapy and a stem cell transplant, participants received specially grown HIV-fighting immune cells (HST-NEETs). The goal was to see if giving these cells was feasible and if they could r…
Phase 2 • Sponsor: Catherine Bollard • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
High-Dose chemo and stem cell transplant shows promise for HIV lymphoma patients
Disease control CompletedThis early-phase trial tested whether high-dose chemotherapy followed by a stem cell transplant is safe and feasible for 25 people with HIV who also have lymphoma. The goal was to see how well the body recovers and to monitor side effects. Results could point to a new treatment p…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo shows promise for tough lymphomas
Disease control CompletedThis study tested adding lenalidomide to a standard chemotherapy regimen (EPOCH-R) in 55 people with aggressive B-cell lymphomas linked to the MYC gene. The goal was to find the best dose and see if the combination improves how long patients live without their cancer getting wors…
Phase 1/2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC